For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields ...

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) stock is trading lower on Thursday. The company released patient updates on ...

Opdivo showed a 52% progression-free survival advantage over Adcetris in newly diagnosed Hodgkin’s lymphoma, according to a ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, ...

Patients with gallbladder cancer and cholangiocarcinoma may benefit from receiving Avastin plus Tarceva versus active ...

Researchers investigated whether induction chemotherapy improves PFS and OS in patients with locally advanced cervical cancer ...

The drug combined with chemotherapy demonstrated a 60% increase in progression-free survival, suggesting signs of an FDA ...

A new combination therapy of lurbinectedin and atezolizumab showed promising results in improving overall survival and ...

Nivolumab plus AVD “should be a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin’s lymphoma,” according to researchers.

Nektar Therapeutics said that a phase 1 study examining a combination of NKTR-255 in combination with an autologous ...

Short-course induction chemotherapy prior to chemoradiotherapy should be considered a standard of care, according to ...

Long-term results support the use of capmatinib in patients with previously treated or untreated METex14 NSCLC, according to researchers.